Theranos CEO Elizabeth Holmes to speak at clinical chemistry conference

Theranos CEO Elizabeth Holmes is expected to speak at the American Association for Clinical Chemistry’s annual meeting on Aug. 1 in Philadelphia and present data on the embattled company’s technologies. But, as STAT reports, it is unclear how much Holmes will divulge as the company has no peer-reviewed data and is facing scrutiny from the federal government.

Holmes’s appearance will be the first time she will have publicly discussed Theranos’s technologies, which include a device to collect blood through a finger prick. On July 7, the Centers for Medicare & Medicaid Services (CMS) barred Holmes from owning, operating or directing a laboratory for at least two years after inspecting one of Theranos’s laboratories in Newark, California. CMS also revoked the company’s certification for that laboratory.

Read the full STAT article below:

Tim Casey,

Executive Editor

Tim Casey joined TriMed Media Group in 2015 as Executive Editor. For the previous four years, he worked as an editor and writer for HMP Communications, primarily focused on covering managed care issues and reporting from medical and health care conferences. He was also a staff reporter at the Sacramento Bee for more than four years covering professional, college and high school sports. He earned his undergraduate degree in psychology from the University of Notre Dame and his MBA degree from Georgetown University.

Around the web

Several key trends were evident at the Radiological Society of North America 2024 meeting, including new CT and MR technology and evolving adoption of artificial intelligence.

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.